No products in the cart.

Hero CMP-20 CBGA vs CBDA
Home/ Compare/ CBGa vs CBDa

CBGa vs CBDa: One Precursor, Three Enzymes Competing For It

CBGa is the acid precursor a cannabis plant assembles first, and CBDa is what one enzyme, CBDA synthase, converts it into. In a CBD-type cultivar nearly all of the CBGa is drawn down that way, which is why CBDa dominates fresh unheated hemp and CBGa does not.

Neither has been studied on its own in a controlled trial in people. Everything published about both comes from cell assays and animals.

Third Party Tested Batch Certificates Of Analysis Highest Quality Full Spectrum Global Shipping 100% Organic
Third Party Tested Batch Certificates Of Analysis Highest Quality Full Spectrum Global Shipping 100% Organic

At a glance

Property
CBGa
CBDa
What it is
The first cannabinoid a plant builds, from olivetolic acid and geranyl pyrophosphate
The acid form of CBD, and the main cannabinoid in fresh unheated hemp
Where it comes from
Synthesised by the plant, then drawn down by three competing synthase enzymes
Produced from CBGa by CBDA synthase, a 74 kDa enzyme needing no cofactor
CB1 receptor
No binding affinity at CB1 has been published
Ki above 10,000 nM at human CB1 in CHO cell membranes
CB2 receptor
No binding affinity at CB2 has been published
Ki 12 nM at human CB2, reaching 32% of the reference effect on cAMP
Most potent measured target
Store-operated calcium entry, where it was the most potent cannabinoid tested in immune cell lines
5-HT1A, increasing agonist-stimulated GTP binding in rat brainstem membranes
Intoxicating
No, and no dose has ever been given to a person in a published study
No, including in the single human study of a product containing it
Human trials
None of isolated CBGa
None of isolated CBDa. One 15-person study used a 1:1 CBD to CBDa product
Human pharmacokinetics
None published. The absorption work was done in dogs and horses
Peak plasma concentration 19 to 25 times that of CBD from the same product

One substrate, three enzymes competing for it

A cannabis plant does not synthesise CBD, THC or CBC. It synthesises CBGa, and three enzymes then compete to cyclise that single pool into CBDa, THCa or CBCa. Which of those enzymes a plant carries in working form is what fixes its chemotype long before harvest.

CBDA synthase was isolated and characterised in 1996 as a single polypeptide of 74 kDa with an isoelectric point of 6.1. It requires no coenzyme, no molecular oxygen, no hydrogen peroxide and no metal ion, which excludes it from being either an oxygenase or a peroxidase. It will also accept cannabinerolic acid, but the turnover number there is 0.03 per second against 0.19 per second for CBGa, so CBGa is the route that matters in a living plant.

That explains what a CBGa figure on a certificate of analysis represents. CBGa is unconsumed substrate, not a separate product the plant adds at the end. Varieties carrying a defective synthase accumulate it because nothing draws it down, and an earlier harvest leaves more behind. Heat then separates the two again, turning residual CBGa into CBG and CBDa into CBD.

What has actually been measured for each

CMP-20 CBGA vs CBDA second section

CBGa’s most potent recorded activity is nowhere near a cannabinoid receptor. Tested against store-operated calcium entry in several immune cell lines, the acid cannabinoids outperformed both CBD and THC, and CBGa was the most potent of them, blocking calcium release-activated calcium currents and reducing NFAT activation and interleukin 2 production in cultured human T lymphocytes. A second group reported CBGa as the strongest cannabinoid inhibitor of the TRPM7 channel, and showed the effect disappears when TRPM7’s kinase domain is not functional.

CBDa’s clearest result is at 5-HT1A, where it raised the maximum effect of a 5-HT1A agonist on GTP binding in rat brainstem membranes. The animal work that followed used strikingly low doses: 0.1 and 0.5 mg per kilogram in shrews, and 0.01 and 0.1 mg per kilogram in rats. Both acids were also shown to bind the SARS-CoV-2 spike protein at micromolar affinity in vitro.

None of that was measured in a person, and no claim about either compound is authorised here. What can be stated is what the assays recorded, which is what this page restricts itself to.

The evidence, side by side

CBGa
In Scn1a+/- mice, CBGa raised the threshold for hyperthermia-induced seizures and added to the effect of clobazam, the strongest hit in a screen of the whole plant.
In that same study CBGa was proconvulsant in the 6 Hz threshold test, and a high dose raised spontaneous seizure frequency in the same mice.
No controlled trial of isolated CBGa in people has been published, so no human dose range exists for it.
CBDa
In 15 healthy adults given a 1:1 CBD to CBDa product, CBDa peak plasma concentration was 19 to 25 times that of CBD and was reached up to twice as quickly.
That same product also contained THC and THCa, so nothing it produced in those participants can be attributed to CBDa alone.
CBDa reduced motion-induced and toxin-induced vomiting in shrews at 0.1 and 0.5 mg per kilogram, by a 5-HT1A route rather than a CB1 one.
No controlled trial of isolated CBDa in people has been published, and no endpoint has been tested in humans.

The imbalance between the two columns is the useful part. CBDa carries the better animal pharmacology and the only human absorption figure of the pair, and that figure came from a mixture rather than from CBDa by itself. CBGa carries the more striking in vitro potency.

What people get wrong

01 The acids are just the same molecules with an extra piece attached.
The carboxyl group changes how they behave. CBDa fails to displace a cannabinoid ligand from CB1 at 10,000 nM where CBD manages it weakly, and the acid forms reach higher plasma concentrations faster than their neutral counterparts.
02 Raw oil is stronger because nothing has been cooked out.
Heating converts the acids rather than removing activity, so raw and decarboxylated extracts differ in profile rather than strength. For the acid forms there is no human efficacy data for either to be stronger or weaker than.
03 CBGa is scarce, so it must be worth more.
CBGa is leftover substrate. Plants with a defective synthase accumulate it, and an early harvest leaves more behind. Its scarcity in ordinary hemp is a fact about agronomy and enzyme genetics, not about the molecule.

Choosing between them

This is less a choice between two compounds than a choice about heat. An unheated full spectrum extract keeps CBDa as its principal cannabinoid with CBGa present in smaller amounts, because neither has been decarboxylated. Heat the same material and you get CBD and CBG instead.

Decide on that basis, and recognise that you are selecting a profile rather than an evidence base. CBDa has the larger body of animal work and the only human absorption measurement. CBGa has the most potent single in vitro result. Neither has an outcome measured in people.

How Endoca tests for this

Our HPLC panel reports acid and neutral forms as separate analytes, which is the only way to demonstrate that an unheated extract really is unheated. A raw batch shows CBDa dominant with CBD and CBG low, and a decarboxylated batch shows the reverse. Where a cannabinoid sits below the limit of quantification we record it as such rather than estimating. A certificate cannot say what either acid does at a receptor.

Frequently asked questions

Yes. CBDA synthase converts CBGa directly into CBDa with a turnover number of 0.19 per second. The same CBGa pool also feeds THCa synthase and CBCa synthase, so all three acids compete for one substrate, and the enzymes a plant carries decide its chemotype.

Both, in very unequal amounts. An unheated CBD-type extract is dominated by CBDa because the plant converted most of its available CBGa before harvest. CBGa appears in smaller amounts as unconsumed substrate. Heating that material converts the CBDa to CBD and the residual CBGa to CBG.

CBDa does, and efficiently. In 15 healthy adults taking equal amounts of CBD and CBDa in one product, the acid reached peak plasma concentrations 19 to 25 times higher and reached them sooner. No comparable measurement in people has been published for CBGa, only work in dogs and horses.

There is no evidence either way, because neither acid has been through a controlled trial in people. What the data shows is that the acids are absorbed more readily and interact with a different set of targets. Faster absorption of a compound with no human outcome data establishes nothing.

References

01

Taura F, Morimoto S, Shoyama Y. Purification and characterisation of cannabidiolic-acid synthase from Cannabis sativa L. J Biol Chem 1996;271:17411-17416.

02

Taura F et al. Cannabidiolic-acid synthase, the chemotype-determining enzyme in fibre-type Cannabis sativa. FEBS Lett 2007;581:2929-2934.

03

Anderson LL et al. Cannabigerolic acid exhibits divergent effects on seizures in mouse models of epilepsy. Br J Pharmacol 2021;178:4826-4841.

04

Faouzi M et al. Acidic cannabinoids suppress proinflammatory cytokine release by blocking store-operated calcium entry. Function (Oxf) 2022;3:zqac033.

05

Suzuki S et al. Cannabigerolic acid (CBGA) inhibits the TRPM7 ion channel through its kinase domain. Function (Oxf) 2024;5:zqad069.

06

Bolognini D et al. Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol 2013;168:1456-1470.

07

Zagzoog A et al. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Sci Rep 2020;10:20405.

08

Elder HJ et al. Pharmacokinetics and pharmacodynamics of a hemp-derived full-spectrum oral cannabinoid product with a 1:1 ratio of cannabidiol to cannabidiolic acid. Cannabis Cannabinoid Res 2025;10:e299-e313.

09

De Petrocellis L et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163:1479-1494.

10

van Breemen RB et al. Cannabinoids block cellular entry of SARS-CoV-2 and the emerging variants. J Nat Prod 2022;85:176-184.

11

Food Standards Agency. CBD novel food applications: recommendations to ministers on first authorisations. FSA Board paper, September 2026.

Last reviewed 6 October 2026.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.